Core Viewpoint - Agenus Inc. is hosting a Stakeholder Webcast on March 31, 2026, to discuss the progress of its immunotherapy program combining botensilimab (BOT) and balstilimab (BAL), focusing on expanding patient access and development across various tumor types [1][2]. Group 1: Company Overview - Agenus is a leader in immuno-oncology, founded in 1994, with a mission to enhance patient access to cancer immunotherapy through a comprehensive pipeline of immunological agents [4]. - The company has robust development capabilities, including commercial and clinical cGMP manufacturing, research, and global clinical operations [4]. Group 2: Webcast Details - The webcast will be moderated by Garo H. Armen, PhD, the Founder, Chairman, and CEO of Agenus, and will include a live Q&A session [2]. - This event is part of Agenus' 2026 Stakeholder Briefing Series, building on previous discussions about BOT+BAL's clinical progress and patient access pathways [2]. Group 3: Strategic Direction and Clinical Progress - Garo Armen will discuss the urgency of advancing new treatment options for patients with historically treatment-resistant cancers and outline key priorities for 2026 [3]. - Steven J. O'Day, MD, will provide insights into the durability and consistency of BOT+BAL across various tumor types, including those resistant to immunotherapy [3]. Group 4: Patient Access Programs - Kamel Djazouli, MD, will update on Agenus' global access programs, such as the France AAC and Named Patient Programs, which are facilitating treatment for patients with limited options [3].

Core Insights - Agenus Inc. has triggered a $20 million contingent payment under its strategic collaboration with Zydus Lifesciences Ltd. [1] - The payment is linked to contracted work orders for critical chemistry, manufacturing, and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL) [1] Company Summary - Agenus Inc. is recognized as a leader in immuno-oncology innovation [1] - The collaboration with Zydus Lifesciences is focused on advancing the development of botensilimab and balstilimab [1]

Core Viewpoint - Agenus Inc. is set to release its fourth quarter and year-end 2025 financial results on March 16, 2026, before market opening, indicating a focus on transparency and stakeholder engagement [1] Financial Results Announcement - The financial results will be disclosed before the market opens on March 16, 2026, highlighting the company's commitment to timely reporting [1] - A stakeholder briefing webcast will be held in late March to discuss strategic plans and data milestones [1] Development Programs - The company will provide updates on the global development programs for botensilimab (BOT) and balstilimab (BAL), which are key components of its immuno-oncology portfolio [1]

Core Insights - Agenus presented new biomarker data demonstrating survival stratification in microsatellite-stable metastatic colorectal cancer (MSS mCRC) and other immunologically cold tumors treated with the combination of botensilimab (BOT) and balstilimab (BAL) [1] Group 1: Clinical Trial Findings - The Phase 1b C-800-01 trial evaluated BOT in combination with BAL, showing that survival outcomes are influenced by systemic inflammation and tumor immune activity [1] - In 341 efficacy-evaluable patients, the 24-month overall survival rate was 38%, with a median overall survival of 17.2 months, a clinical benefit rate of 26%, and an objective response rate of 17% [1] - Clinical activity was observed across various tumor types, including MSS mCRC, ovarian cancer, sarcoma, and non-small cell lung cancer, with durable benefits noted in patients both naïve to and resistant to prior therapies [1] Group 2: Biomarker Insights - The integration of blood and tumor biomarkers improved survival stratification in MSS mCRC, identifying distinct patient subgroups with different survival outcomes, achieving a C-index of up to 0.73 [1] - Patients experiencing immune-mediated adverse events (imAEs) within the first 12 weeks of treatment had a longer median overall survival of 22.4 months compared to 13.7 months for those without imAEs [1] - Elevated systemic inflammation markers, such as the neutrophil-to-lymphocyte ratio and C-reactive protein, were significantly associated with shorter overall survival [1] Group 3: Mechanism of Action - Botensilimab is designed to enhance both innate and adaptive anti-tumor immune responses, potentially extending immunotherapy benefits to cold tumors that typically respond poorly to standard treatments [2] - The Fc-enhanced mechanism of BOT allows for clinical benefits even at low levels of immune infiltration, suggesting a lower threshold of baseline immunity is required for activity [1] - Approximately 1,200 patients have been treated with BOT and/or BAL in clinical trials, demonstrating clinical responses across nine metastatic, late-line cancers [2]

Core Insights - Agenus Inc. announced new data from its botensilimab (BOT) immunotherapy program will be presented at the AACR-IO Conference, focusing on systemic and tumor inflammation biomarkers in immunologically cold tumors [1] Group 1: Presentation Details - The poster presentation titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab" will evaluate the association of systemic inflammatory markers and tumor microenvironment immune activity with clinical outcomes [1] - The presentation will take place on February 19, 2026, from 12:15 PM to 3:15 PM PT at the JW Marriott, Platinum Ballroom [1] Group 2: About Botensilimab and Balstilimab - Botensilimab is designed to enhance both innate and adaptive anti-tumor immune responses, particularly in "cold" tumors that typically respond poorly to standard therapies [1] - Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in clinical trials, showing clinical responses across nine metastatic, late-line cancers [1] - Balstilimab is a fully human monoclonal antibody that blocks PD-1 from interacting with its ligands, having been evaluated in over 900 patients with a favorable tolerability profile [1] Group 3: Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994, aiming to expand patient populations benefiting from cancer immunotherapy [1] - The company has robust development capabilities, including commercial and clinical cGMP manufacturing facilities, research, and global clinical operations [1]

Core Insights - Agenus Inc. has appointed José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025 [1] - Dr. Iglesias will oversee global medical affairs for botensilimab (BOT) and balstilimab (BAL) as they progress through Phase 3 evaluation [1] - The combination of BOT and BAL will be made available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel [1]

Core Insights - Agenus Inc. will host a virtual Stakeholder Briefing on October 21, 2025, focusing on updates regarding its immunotherapy combination botensilimab (BOT) and balstilimab (BAL) [1][3] - The briefing will feature insights from leading experts on recent clinical progress and expanding international access for BOT/BAL, moderated by Garo Armen, PhD, the company's CEO [1][3] Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994 [4] - The company aims to expand patient populations benefiting from cancer immunotherapy through combination approaches, utilizing a variety of therapeutic methods [4] Product Information - Botensilimab (BOT) is designed to enhance anti-tumor immune responses and is effective in treating "cold" tumors that typically respond poorly to standard therapies [5][6] - Approximately 1,200 patients have been treated with BOT/BAL in phase 1 and phase 2 clinical trials, showing clinical responses across nine metastatic, late-line cancers [7] - Balstilimab (BAL) is a fully human monoclonal antibody that blocks PD-1 interactions, demonstrating clinical activity in over 900 patients [8]